Peptides
Precision Medicine for Healing, Performance & Longevity
Peptides Are Natural Messengers in the Body
Peptides are short chains of amino acids that act as signaling molecules, helping regulate functions like metabolism, immune response, and tissue repair (Rossino et al., 2023).
What makes them relevant in medicine is how they interact with the body’s existing biology. By binding to specific receptors, peptides are understood to affect targeted biological pathways. The clinical impact of these interactions depends on the individual peptide and the strength of available evidence.
This is not a new frontier. It reflects mechanisms medicine has relied on for decades. Many well-established therapies are peptide-based, including insulin, oxytocin, calcitonin, and GLP-1 receptor agonists (Rossino, 2026).
Peptide Therapeutics Have a Long History
Peptides have been used in clinical medicine for more than a century. In 1921, insulin became the first therapeutic peptide, transforming the treatment of diabetes and establishing a foundation for peptide-based therapies (Rossino, 2026).
Advances in recombinant DNA technology later enabled the development of additional peptide therapies, including GnRH analogs, somatostatin analogs, and calcitonin derivatives (Wang, 2022).
What has changed in recent years is the pace and scope of research. Peptide development has expanded into areas such as metabolic disease, oncology, autoimmune conditions, and reproductive medicine.
More recently, attention has turned toward what some providers are calling “functional peptides.” This includes thymosin peptides, mitochondrial-derived peptides like MOTS-c, growth hormone secretagogues, and angiogenic peptides.
Many of these remain investigational, highlighting the distinction between established therapies and emerging areas of study (Wang, 2022; Bellman-Sickert et al., 2018; Singh et al., 2022).
Peptides Are a Growing Segment of the Pharmaceutical Market
Peptide therapeutics are no longer a niche category. Today, they represent an estimated 5–10% of the global pharmaceutical market, with continued growth driven by ongoing research and clinical interest (Grandview Research, 2023).
Because peptides can target specific biological pathways and receptors, they are being studied as a way to better understand and potentially influence processes such as hormone signaling and immune response.
This has contributed to the development and approval of more than 100 peptide-based drugs globally, alongside a growing research pipeline (Musiami, 2024).
Regulatory Frameworks Are Central to Peptide Use
As interest in peptides has expanded, so has the importance of regulatory oversight. Peptides may be available as FDA-approved drugs or, in certain cases, as compounded preparations under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDA, 2021).
In response to the growing use of peptides, in 2023 the FDA identified potential significant safety risks of certain bulk substances used in compounding. These substances are evaluated based on safety and available evidence, with certain peptides categorized as ineligible for compounding due to potential risk (FDA, 2025).
Recent FDA communications and actions suggest a continued evolution in policy related to compounding and the use of certain bulk substances, including peptides. This includes ongoing evaluation of substances nominated for compounding, clarification of enforcement priorities, and increased emphasis on aligning compounding practices with statutory and evidentiary standards.
Collectively, these signals indicate that additional regulatory guidance or policy refinement may be forthcoming as the Agency continues to assess safety, quality, and appropriate use within this category (FDA, 2024).
For both providers and patients, this regulatory landscape is central to understanding how peptide therapies are evaluated, accessed, and used.
Clinical Use Requires Attention to Evidence, Quality, and Oversight
Peptides are being studied and, in some cases, used in clinical practice across areas such as metabolic and endocrine conditions. Other potential applications, including those often discussed in regenerative contexts, remain investigational and continue to be evaluated.
At the same time, demand has expanded beyond traditional clinical and regulatory channels (Hahamyan et al., 2025). Some peptides are marketed through “research use” suppliers and other unregulated sources, often without consistent quality standards or clinical oversight.
This gap between growing demand and uneven evidence makes a clinically grounded approach essential. The use of peptide therapies should prioritize evidence-based decision-making where available, careful evaluation of risks and benefits, appropriate regulatory alignment, and ongoing attention to emerging safety data (Petrou et al., 2025).
Peptides occupy an important and evolving role in modern medicine.
Some therapies are well established, supported by decades of clinical use and robust evidence. Others remain investigational, with ongoing scientific study and regulatory evaluation.
Understanding the distinction between these categories is essential to informed clinical decision-making.
As interest continues to grow, the path forward requires balancing scientific progress with evidence, safety, and appropriate oversight.